newsfilter
← Latest News
GlobeNewswire·

Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026

  • Grace Therapeutics, Inc. (NASDAQ: GRCE) announced participation in upcoming healthcare industry & investor conferences during November 2026.
  • Chief Executive Officer Prashant Kohli will attend BIO-Europe 2026 in Cologne, Germany, from November 9-11, 2026.
  • Mr. Kohli will also attend the Craig-Hallum 17th Annual Alpha Select Conference on November 17, 2026, in New York, NY.
  • The company's lead clinical asset, GTx-104, is an injectable nimodipine formulation for IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH).
  • GTx-104 has received Orphan Drug Designation from the FDA, granting seven years of marketing exclusivity upon NDA approval.
  • The drug candidate holds 52 granted & pending patents & utilizes novel drug delivery technology to potentially improve efficacy & reduce side effects.
  • Forward-looking statements address risks related to FDA resubmission of the NDA, manufacturing compliance, non-clinical studies, & potential capital needs.
  • The press release includes contact details for CEO Prashant Kohli & Investor Relations at LifeSci Advisors.